A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
Completed · Phase 3 · NCT07284381
Conditions: Dry Eye Disease
At a glance
- Research payments reported, 2025
- $3,284
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 261
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-444 (drug), REFRESH OPTIVE UD (drug)
- Dates
- Started 2025-12-15; completion 2026-08-21
- Results posted
- Not yet
Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at appro…
From ClinicalTrials.gov, last updated 2026-09-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $3,284 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Michael J. Depenbusch, M.D. Ophthalmology · Chandler, AZ
- Eran Duzman, M.D. Ophthalmology · Irvine, CA
- Sherif M. El-harazi, MD MPH Ophthalmology · Glendale, CA
- David L. Wirta, MD Ophthalmology · Newport Beach, CA
- Philip L. Shettle, D.O. Ophthalmology · Largo, FL
- Lauren M. Dubiner, MD Ophthalmology · Morrow, GA
- Patrick Vollmer, O.D. Optometrists · Shelby, NC
- Natasha Hindman, O.D. Optometrists · Cranberry Twp, PA
- David G. Evans, OD Optometrists · Memphis, TN
- Gary W. Jerkins, MD Ophthalmology · Nashville, TN
- James D. Paauw, M.D. Ophthalmology · Lynchburg, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Core Inc $375
- Eye Research Foundation Inc $293
- Doctrials $291
- Scott and Christie Eyecare Associates PC $291
- Advancing Vision Research LLC $291
- Global Research Management $291
- Clayton Eye Center $291
- Shettle Eye Research Inc $291
- Lakeside Vision Center $291
- Piedmont Eye Center $291
- Total Eye Care PA $291
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.